Literature DB >> 36240062

Overexpression and ELISA-based detection of asprosin in cultured cells and mice.

Ila Mishra1, Atul R Chopra2.   

Abstract

The unreliability of commercial recombinant asprosin preparations and variability between asprosin detection assays have proven to be a bottleneck in experimental interpretation. This protocol describes the use of viral vectors and expression plasmid for overexpression and secretion of human asprosin to achieve sustained elevation of asprosin protein in mice and HEK293T cells without using recombinant proteins. This protocol also includes a sandwich ELISA using anti-asprosin monoclonal antibodies for detection of asprosin in media from cultured cells and in plasma of mice. For complete details on the use and execution of this protocol, please refer to Duerrschmid et al. (2017), Mishra et al. (2021), and Mishra et al. (2022).
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Gene expression; Metabolism; Molecular biology; Molecular/Chemical probes; Neuroscience

Year:  2022        PMID: 36240062      PMCID: PMC9568886          DOI: 10.1016/j.xpro.2022.101762

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


  10 in total

1.  Detection of Transgenic Proteins by Immunoassays.

Authors:  Satyalinga Srinivas Gampala; Bryant Wulfkuhle; Kimberly A Richey
Journal:  Methods Mol Biol       Date:  2019

2.  Impact assessment of tail-vein injection in mice using a modified anaesthesia induction chamber versus a common restrainer without anaesthesia.

Authors:  Marlene Resch; Tania Neels; Alexander Tichy; Rupert Palme; Thomas Rülicke
Journal:  Lab Anim       Date:  2018-08-08       Impact factor: 2.471

Review 3.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

4.  A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model.

Authors:  Junko Yano; Elizabeth A Lilly; Mairi C Noverr; Paul L Fidel
Journal:  J Vis Exp       Date:  2020-11-06       Impact factor: 1.355

5.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582

Review 6.  Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Authors:  Mehmet Akif Ovali; Ibrahim Bozgeyik
Journal:  Mol Syndromol       Date:  2022-02-08

7.  Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor.

Authors:  Ila Mishra; Wei Rose Xie; Juan C Bournat; Yang He; Chunmei Wang; Elizabeth Sabath Silva; Hailan Liu; Zhiqiang Ku; Yinghua Chen; Bernadette O Erokwu; Peilin Jia; Zhongming Zhao; Zhiqiang An; Chris A Flask; Yanlin He; Yong Xu; Atul R Chopra
Journal:  Cell Metab       Date:  2022-03-16       Impact factor: 31.373

8.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

9.  Asprosin-neutralizing antibodies as a treatment for metabolic syndrome.

Authors:  Ila Mishra; Clemens Duerrschmid; Zhiqiang Ku; Yang He; Wei Xie; Elizabeth Sabath Silva; Jennifer Hoffman; Wei Xin; Ningyan Zhang; Yong Xu; Zhiqiang An; Atul R Chopra
Journal:  Elife       Date:  2021-04-27       Impact factor: 8.140

10.  Asprosin is a centrally acting orexigenic hormone.

Authors:  Clemens Duerrschmid; Yanlin He; Chunmei Wang; Chia Li; Juan C Bournat; Chase Romere; Pradip K Saha; Mark E Lee; Kevin J Phillips; Mahim Jain; Peilin Jia; Zhongming Zhao; Monica Farias; Qi Wu; Dianna M Milewicz; V Reid Sutton; David D Moore; Nancy F Butte; Michael J Krashes; Yong Xu; Atul R Chopra
Journal:  Nat Med       Date:  2017-11-06       Impact factor: 53.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.